Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COMMUNITY HEALTH SYSTEMS INCCYH · Entity 5628 | EVP-Clinical Operations & CMO | June 01, 2026 | June 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COMMUNITY HEALTH SYSTEMS INC
Report date June 01, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
After 2026-06-01 transaction · row 1
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 30,000 · Balance 30,000 F1: The time-vesting restrictions on this award of restricted stock will lapse in 1/3 increments on the first, second and third anniversary of the date of grant. |
| Performance Based RestrictedSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 30,000 |
Reported balance
After 2026-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-01 · Grant · Acquired 30,000 · Balance 30,000 F2: The vesting of these performance-based restricted shares is allocated to the Issuer's attainment of the following predetermined performance objectives between 1/1/2026 and 12/31/2028 (the "2026-2028 Performance Period"), as follows: 50% to a Cumulative Same-Store Adjusted EBITDA Growth target; and 50% to a Cumulative Same-Store Net Revenue Growth target. The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each performance objective will ultimately vest on 3/1/2029, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2026-2028 Performance Period. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.75 · Expires 2036-05-31 | Direct | 30,000 |
Reported balance
After 2026-06-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-01 · Grant · Acquired 30,000 · Balance 30,000 F3: Vesting occurs in 1/3 increments on the first, second and third anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The time-vesting restrictions on this award of restricted stock will lapse in 1/3 increments on the first, second and third anniversary of the date of grant.
F2: The vesting of these performance-based restricted shares is allocated to the Issuer's attainment of the following predetermined performance objectives between 1/1/2026 and 12/31/2028 (the "2026-2028 Performance Period"), as follows: 50% to a Cumulative Same-Store Adjusted EBITDA Growth target; and 50% to a Cumulative Same-Store Net Revenue Growth target. The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each performance objective will ultimately vest on 3/1/2029, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2026-2028 Performance Period.
F3: Vesting occurs in 1/3 increments on the first, second and third anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 1, 2026 21:38 UTC | COMMUNITY HEALTH SYSTEMS INC CYH · Entity 5628 | GrantStock Options (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001193125-26-251834 · ownership.xml · derivative · entry 3 Rice David V. · CIK 0002135141 · EVP-Clinical Operations & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-05-31 F3 · derivative.exercise_date: Vesting occurs in 1/3 increments on the first, second and third anniversary of the date of grant. Read SEC document |
| June 01, 2026 Filed Jun 1, 2026 21:38 UTC | COMMUNITY HEALTH SYSTEMS INC CYH · Entity 5628 | GrantPerformance Based Restricted · Derivative | 30,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-251834 · ownership.xml · derivative · entry 2 Rice David V. · CIK 0002135141 · EVP-Clinical Operations & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F2 · derivative.exercise_date: The vesting of these performance-based restricted shares is allocated to the Issuer's attainment of the following predetermined performance objectives between 1/1/2026 and 12/31/2028 (the "2026-2028 Performance Period"), as follows: 50% to a Cumulative Same-Store Adjusted EBITDA Growth target; and 50% to a Cumulative Same-Store Net Revenue Growth target. The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each performance objective will ultimately vest on 3/1/2029, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2026-2028 Performance Period. F2 · derivative.expiration_date: The vesting of these performance-based restricted shares is allocated to the Issuer's attainment of the following predetermined performance objectives between 1/1/2026 and 12/31/2028 (the "2026-2028 Performance Period"), as follows: 50% to a Cumulative Same-Store Adjusted EBITDA Growth target; and 50% to a Cumulative Same-Store Net Revenue Growth target. The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each performance objective will ultimately vest on 3/1/2029, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2026-2028 Performance Period. Read SEC document |
| June 01, 2026 Filed Jun 1, 2026 21:38 UTC | COMMUNITY HEALTH SYSTEMS INC CYH · Entity 5628 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-251834 · ownership.xml · nonDerivative · entry 1 Rice David V. · CIK 0002135141 · EVP-Clinical Operations & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 F1 · shares: The time-vesting restrictions on this award of restricted stock will lapse in 1/3 increments on the first, second and third anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.